Published:11/09/2018
Chippenham, UK – 11 September 2018: Vectura Group plc (LSE: VEC) (“Vectura” or “the Group”) announces its unaudited Interim Results for the six months ended 30 June 2018 and reiterates its current guidance for the full year.
Commenting on the results, James Ward-Lilley, Chief Executive Officer of Vectura, said: “Vectura is regaining momentum after a challenging 2017. Inhaled in-market growth is continuing with flutiform® stock levels normalising resulting in total inhaled Vectura revenues increasing 7.1% vs H1 2017.
“Our refocussed pipeline is making progress with Phase II VR647 results a key highlight in H1 2018. We have identified and are progressing a series of new pipeline projects, and we look forward to the read-out of the VR475 Phase III adult asthma study later this year.
“With positive in-market momentum and additional pipeline catalysts, we look forward to delivering against our strategy in the second half of 2018 and we maintain our full-year guidance.”
